Annovis Bio Rallies On Missed ITT Parkinson's Study Endpoints [Seeking Alpha]
Annovis Bio, Inc. (ANVS)
Company Research
Source: Seeking Alpha
Jul. 08, 2024 1:52 PM ET Annovis Bio, Inc. (ANVS) Stock 2 Comments AR Capital Menagement Follower s Follow Summary Analysis of Annovis Bio's lead product, buntanetap, tested in neurodegenerative diseases suggests questionable efficacy, in our opinion. Recent topline data from the PD phase 3 study shows no efficacy in the ITT population among positive post-hoc claims. The company intends to meet with the FDA and discuss an NDA filing, which, we believe, is currently not supported by the available evidence. Financial constraints persist, with ~$4M cash left on the balance sheet. Al Gonzalez/iStock via Getty Images Introduction This article provides an update on our previous analyses of Annovis Bio ( NYSE: ANVS ), focusing on their lead product, buntanetap (phenserine). Our initial analysis delved into the extensive preclinical and clinical findings, critically evaluating Recommended For You
Show less
Read more
Impact Snapshot
Event Time:
ANVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANVS alerts
High impacting Annovis Bio, Inc. news events
Weekly update
A roundup of the hottest topics
ANVS
News
- Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and MorePR Newswire
- Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative DiseasesGlobeNewswire
- Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative CombinationsGlobeNewswire
ANVS
Earnings
- 5/10/24 - Beat
ANVS
Sec Filings
- 9/30/24 - Form 8-K
- 8/15/24 - Form 8-K
- 8/14/24 - Form 10-Q
- ANVS's page on the SEC website